MAPK3 and head and neck cancer: Similarly, another recently published study has shown that dehydrocrenatidine prevents head and neck cancer cell motility, migration, and invasion by inhibiting ERK1/2 and JNK1/2 phosphorylation and reducing MMP-2 expression [21].